Cargando…

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiehn, Oliver, Showalter, Megan Reed, Schaner-Tooley, Christine E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2016
Materias:	Biochemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786416/ https://www.ncbi.nlm.nih.gov/pubmed/26943899 http://dx.doi.org/10.7554/eLife.12626

Ejemplares similares

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Showalter, Megan Reed, et al.
Publicado: (2017)

Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
por: Evans, Brad, et al.
Publicado: (2015)

D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2
por: Lin, An-Ping, et al.
Publicado: (2015)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
por: Akbay, Esra A., et al.
Publicado: (2014)

Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation
por: KAWAKAMI, Shota, et al.
Publicado: (2017)

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
por: Chittaranjan, Suganthi, et al.
Publicado: (2014)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
por: Leather, Thomas, et al.
Publicado: (2017)

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
por: Richardson, Leland G., et al.
Publicado: (2019)

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
por: Kotredes, Kevin P., et al.
Publicado: (2019)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
por: Viswanath, Pavithra, et al.
Publicado: (2018)

Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
por: Longuespée, Rémi, et al.
Publicado: (2018)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

UBE2G1 governs the destruction of cereblon neomorphic substrates
por: Lu, Gang, et al.
Publicado: (2018)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
por: Ma, Shenghong, et al.
Publicado: (2015)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Andronesi, Ovidiu C., et al.
Publicado: (2018)

OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation
por: Mortazavi, Armin, et al.
Publicado: (2021)

Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas
por: Autry, Adam W., et al.
Publicado: (2022)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Serum D‐2‐hydroxyglutarate and the ratio of D‐2HG/L‐2HG predict IDH mutation in acute myeloid leukemia
por: Zhang, Chelsea, et al.
Publicado: (2023)

Treatment with sodium (S)-2-hydroxyglutarate prevents liver injury in an ischemia-reperfusion model in female Wistar rats
por: Cienfuegos-Pecina, Eduardo, et al.
Publicado: (2021)

Diagnostic performance of clinical properties and conventional magnetic resonance imaging for determining the IDH1 mutation status in glioblastoma: a retrospective study
por: Wang, Qun, et al.
Publicado: (2019)

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
por: Hujber, Zoltán, et al.
Publicado: (2017)

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model
por: Wang, Fang, et al.
Publicado: (2016)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
por: Simonin, Mathieu, et al.
Publicado: (2021)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate
por: Sesanto, Rae, et al.
Publicado: (2021)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vv98auan1ndv6o0vpp5053a4bs